Efpeglenatide Improves Renal, Cardiovascular Outcomes in High-Risk Diabetes
Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.
Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.
Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.
Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing.
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Study findings highlight an “unmet need” for newer therapies.
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
These SCS devices were cleared based on data from a randomized controlled trial published in the journal Diabetes Care in 2014.
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.
Findings among patients with type 2 diabetes and history of cardiovascular disease or current kidney disease